Get the Stockscreener App
13.75
3.09%
-0.49
Crescent Biopharma Inc stock is traded at $13.75, with a volume of 4,593.
It is down -3.09% in the last 24 hours and down -18.82% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$14.24
Open:
$14.29
24h Volume:
4,593
Relative Volume:
0.01
Market Cap:
$517.83M
Revenue:
$11.88M
Net Income/Loss:
$-162.08M
P/E Ratio:
-1.1014
EPS:
-12.484
Net Cash Flow:
$-156.43M
1W Performance:
-18.29%
1M Performance:
-18.82%
6M Performance:
+17.15%
1Y Performance:
+11.20%
1-Day Range:
$13.80
$14.29
1-Week Range:
$13.44
$17.04
52-Week Range:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
13.94 | 528.97M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
521.60 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.31 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
193.83 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
957.69 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.53 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Jan-21-26 | Initiated | Guggenheim | Buy |
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to S&P Global BMI Index - marketscreener.com
Crescent Biopharma CSO Jan Pinkas Sells 658 Shares to Cover RSU Tax Withholding - Kalkine Media
Crescent BioPharma Executive Sells 240 Shares to Cover RSU Tax Withholding - Kalkine Media
Crescent Biopharma (CBIO) insider sale covers taxes - Stock Titan
Crescent Biopharma (CBIO) CMO sale covers RSU taxes - Stock Titan
Crescent Biopharma (CBIO) CSO sells stock to cover RSU taxes - Stock Titan
Crescent Biopharma (CBIO) COO offloads shares under pre-set trading plan - Stock Titan
Crescent Biopharma (CBIO) legal chief sells shares to cover RSU taxes - Stock Titan
Crescent Biopharma (NASDAQ: CBIO) CFO offloads 568 shares - Stock Titan
Crescent Biopharma (NASDAQ: CBIO) holder plans 16,775-share Rule 144 sale after recent trades - Stock Titan
Planned 804-share sale at Crescent Biopharma (Nasdaq: CBIO) - Stock Titan
Crescent Biopharma (NASDAQ: CBIO) seller plans new trade after $761K June sale - Stock Titan
After $369,768.98 sale, Crescent Biopharma (NASDAQ: CBIO) officer plans another share sale. - Stock Titan
Crescent Biopharma Price Target Maintained With a $27.00/Share by Wedbush - Moomoo
Certain Warrants of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Certain Options of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Crescent Biopharma at Cantor conference: global trial push By Investing.com - Investing.com South Africa
CBIO: Major clinical milestones and global expansion set for 2027, with key data and partnerships advancing - TradingView
Crescent Biopharma at Cantor conference: global trial push - investing.com
Two employees receive options tied to 58,650 Crescent Biopharma shares - Stock Titan
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsIV Contraction - vinanet.vn
Crescent Biopharma to Present at September Investor Conferences - manilatimes.net
Crescent Biopharma Announces September 2026 Investor Conference Presentations - quiverquant.com
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Balyasny Asset Management L.P. Expands Stake in Crescent Biophar - GuruFocus
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 4.9%Should You Buy? - MarketBeat
Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Gap DownShould You Sell? - MarketBeat
Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support LevelDay Trade Opportunities - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CBIO Q2 2026 Earnings: Narrower-Than-Expected Loss Buoys SharesRevenue Miss Report - vinanet.vn
Q3 EPS Forecast for Crescent Biopharma Lowered by Analyst - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
Perceptive Advisors LLC Lowers Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (CBIO) Gets a Buy from Wedbush - The Globe and Mail
Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 - Quiver Quantitative
Crescent Biopharma: Q2 Earnings Snapshot - KING5.com
Crescent Biopharma posts $24.8 million Q2 net loss - Quiver Quantitative
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
CBIO Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Stock DeclinesEPS Guidance Update - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crescent Biopharma Market Sentiment - Benzinga España
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Institutional Confidence - TradingKey
CBIO Q1 2026 Earnings: Narrower Loss Surprises Analysts as Cash Management ImprovesNet Income Trends - careplusvn.com
CBIO|Crescent Biopharma Ord Shs|Price:16.300|Chg%:-0.730 - TradingKey
Crescent Biopharma (CBIO) Shares Dip 4.3% as Stock Pulls Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Crescent Biopharma grants inducement stock options for 52,500 shares at $15.83 each - Bitget
Two Crescent Biopharma Employees Receive 52,500 Stock Options - Stock Titan
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):